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REVIEW ARTICLE
Antithrombotic Agents After Peripheral Transluminal Angioplasty:
a Review of the Studies, Methods and Evidence for their Use
H. R. Watson*1 and D. Bergqvist2
1Searle European Clinical R&D, Paris, France; 2Department of Surgery, University Hospital, Uppsala, Sweden
Objective: to review published studies and assess the strength of the evidence for the use of antithrombotic agents for
the prevention of re-occlusion after peripheral angioplasty.
Methods: a literature search was performed. All randomised comparative studies with patency assessments or clinical
endpoints were included. The methods and results of the studies were compared and evaluated.
Results: eleven randomised trials were identified, six of them were double blind. The majority of patients included were
those with femoropopliteal lesions. A significant benefit of aspirin in one placebo-controlled study is balanced by no
apparent benefit in another study. No dose-dependent effect of aspirin in the range 50–1000 mg/day has been shown in
any of the four studies investigating such an effect. None of the three studies comparing platelet inhibitors and oral
anticoagulants have shown any differences in outcome and no other well-designed studies of anticoagulants have been
reported.
Conclusions: evidence for a reduction in the likelihood of re-occlusion or restenosis after peripheral transluminal
angioplasty with platelet inhibitors remains equivocal. Evidence for the efficacy of any other agent in this indication is
also lacking.
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Introduction group. Clinical or technical outcomes had to be re-
ported in terms of occlusion, restenosis, patency or
Pharmacological prophylaxis against re-occlusion is symptomatic improvement.
routinely used after percutaneous transluminal an- A literature search of EMBASE and MEDLINE data-
gioplasty (PTA) of arteries in the lower limb.1 However, bases was performed using the following terms:
the agents and doses of antithrombotic agents used angioplasty with either arterial occlusive disease, peri-
vary between centres,2 suggesting that the evidence pheral, leg, femoral artery or popliteal artery and
from published trials may be unclear or insufficiently platelet aggregation inhibitors, aspirin, salicylic acids,
well-known. A meta-analysis of all trials with platelet dipyridamole, ticlopidine, prostaglandins, anti-
inhibitors suggested a value of these agents in pre- coagulants.
venting occlusion in patients with peripheral vascular A detailed evaluation was performed, including all
disease, but only a few of the studies included patients trials which explicitly reported using a process of
undergoing PTA.3 randomisation to allocate patients to treatment arms.
A review of published trials was undertaken in Where necessary for evaluation of the results, ad-
order to assess the current evidence from clinical trials ditional information was sought from the authors.
for the use of antithrombotic agents after PTA.
Methods Results
The studies to be included were comparative clinical Drugs studied and study designs
trials of pharmacotherapy with a concurrent control
Fourteen published comparative studies were iden-
* Please address all correspondence to: H. R. Watson, Searle Euro- tified offering data on the efficacy of various agentspean Clinical R&D, Immeuble Elyse´es–La De´fense, 7 place du Doˆme,
92056 Paris–La De´fense, France. in the prophylaxis of occlusion after PTA (Table 1).
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Table 1. Agents, studies published, patients analysed and study designs.
Agent studied Author Treatments Patients Design*
Aspirin–dipyridamole Heiss 19908 Aspirin 300 mg/dipyridamole 225 mg 47 R, DB, 1C
Aspirin 990 mg/dipyridamole 225 mg 51
Placebo 47
Study group on Aspirin 50 mg/dipyridamole 400 mg 105 R, DB, 12C
PTA 19946 Placebo 110
Staiger 198018 Aspirin 1500 mg 33 NR, O, 1C
Aspirin 900 mg/dipyridamole 225 mg 28
None 39
Hess 19784 Aspirin 990 mg 50 R, DB, 1C
Aspirin 990 mg/dipyridamole 225 mg 51
Ranke 199219 Aspirin 50 mg 184 R, DB, 2C
Aspirin 900 mg 175
Weichert 199420 Aspirin 300 mg 106 R, DB, 2C
Aspirin 1000 mg 105
Minar 19959 Aspirin 100 mg 105 R, O, 1C
Aspirin 1000 mg 102
Suloctidil Mahler 19875 Suloctidil+anticoagulant 48 R, DB, 3C
Placebo+anticoagulant 51
Ticlopidine Schneider 198712 Ticlopidine 103 R, O, 3C
Anticoagulant 94
Iloprost Horrocks 199710 Iloprost 72 h+aspirin 300 mg after 72 h 11 R, O, 2C
Aspirin 300 mg 13
None 72 h+aspirin 300 mg after 72 h 14
Oral anticoagulants Do 199411 Aspirin 50 mg/dipyridamole 400 mg 51 R, O, 1C
Anticoagulant 61
Pilger 19917 Aspirin 500 mg/dipyridamole 225 mg 66 R, O, 1C
Anticoagulant 63
Teteroo 199521 Anticoagulant 129 NR, O, 1C
None 71
Zeitler 197817 Aspirin 1500 mg+anticoagulant 90 NR, O, 1C
Aspirin 1500 mg 87
*R=randomised; NR=non-randomised; O=open; DB=double-blind; nC=number of centres.
Eleven of the studies appeared to have used a ran- ranged from 19% to 76% (median 46%). Where the de-
gree of stenosis on entry was defined, it was always adomisation process for the allocation of patients to
treatment groups, and the methods and results of these reduction in luminal diameter of >50%. The length of
the lesions to be included was sometimes defined pro-eleven studies are evaluated in this review. Six studies
had a double-blind design and three were comparisons spectively, but not always. A successful dilatation,
where defined, was a reduction in stenosis to <50% oc-of active treatment against placebo. Eight of the studies
were conducted in single centres and only one study clusion of the vessel and additionally in some studies
an absolute reduction of >20% in the degree of stenosis.was performed in more than three centres.
The majority of the patients included in each study Patients with failure to cross or satisfactorily dilate a
lesion were usually not randomised. In the case of ran-suffered intermittent claudication, the percentage ran-
ging from 59% to 99% (median 88%). The remainder domisation and treatment prior to PTA, they were
usually excluded from further follow-up in the studies.of the patients had ischaemic rest pain or trophic
lesions. Two studies gave no information on the clinical The results were usually quoted as the number
of patients with patency or occlusion at the site ofstatus of patients on entry into the study.4,5
Seven of the studies included only patients with angioplasty. However, some papers divided patients
into three mutually exclusive categories: patent, re-lesions in the femoropopliteal segment. Four studies
also included patients with iliac lesions, but only one of stenosis or occlusion. In cases where only the number
of patients with patency was given, it was not clearthem included a majority of patients with iliac lesions.6
Most studies included a mixture of stenoses and com- whether the remaining patients had suffered oc-
clusions or might have had only a degree of restenosis.plete occlusions. Only one study exclusively included
patients with occlusions.7 The percentage of patients Three studies gave the results in terms of patients with
improvement in clinical symptoms.7–9with complete occlusions entered in other studies
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The methods for determining patency ranged from Comparisons of aspirin doses
clinical symptoms and pulse palpation to the use of
Four studies have compared the efficacy of differentangiography. Three studies included repeat an-
doses of aspirin after PTA (Table 1). The doses testedgiograms or duplex assessments on all patients during
ranged from 50 mg/day to 1000 mg/day. All of thesefollow-up.4,7,10 All studies employed angiography to
studies were randomised and three of them wereinvestigate restenosis or occlusion suspected on the
double blind. Individually no study has demonstratedbasis of symptoms or arterial pressures.
a statistically significant difference in the incidence ofSample size in terms of the number of procedures
occlusions between the doses tested and no trendsranged from 11 to 192 per treatment group (median
were evident from graphical display of the results108). In several studies there was a discrepancy be-
(Fig. 1). One study comparing aspirin with and withouttween the number of patients and the number of
dipyridamole also failed to show a significant dif-procedures included in the analysis. This was due to
ference between the antiplatelet regimens, althoughthe practice of either entering the same patient into
there was evidence of a trend in favour of the com-the trial on multiple occasions for different procedures
bination.4or entering the patient into one treatment group and
counting each of several procedures separately.
The majority of the studies (seven out of 11) involved
treating and following the patients for 12 months or
longer. The minimum treatment period was 14 days.
Only one study reported a follow-up period of less Comparisons of platelet inhibitors with oral
than 6 months.4 anticoagulants
No double-blind studies of oral anticoagulants after
PTA have been reported and no randomised studies
comparing anticoagulation with an untreated control
group. Prospective, randomised comparisons of thesePlacebo-controlled studies of aspirin
agents with aspirin/dipyridamole7,11 and with ti-
clopidine12 all failed to show any differences in efficacy.There have been two placebo-controlled studies of the
Patency results from these three studies are showncombination of aspirin and dipyridamole, but no such
in Table 3. More frequent bleeding problems werestudy investigating aspirin alone (Table 2). The larger
reported with the anticoagulants overall, includingstudy employed a low dose of aspirin (50 mg/day)
one fatal cerebral haemorrhage.plus dipyridamole (400 mg/day) and found no dif-
ference between the groups with over 100 patients/
treatment arm after a 3-month treatment.6 Patency
(patients without evidence of restenosis or occlusion)
after 3 months was 90% and 95% for aspirin and
placebo, respectively. Patency after 12 months’ follow- Studies with other agents
up was 86% for each group.
A study by Heiss8 with 66–67 patients/treatment An agent for improving the blood flow in patients
arm included two different aspirin-dose groups, with intermittent claudication, suloctidil, has been in-
300 mg/day or 990 mg/day, in combination with di- vestigated in a placebo-controlled trial which showed
pyridamole (225 mg/day). The principal outcome was no effect on the incidence of occlusions or restenosis.5
described as patients improved or did not deteriorate All patients in this study were additionally treated
according to either clinical findings or angiography. with a standard regimen of oral anticoagulants and
Patency was significantly improved with aspirin/di- followed for 12 months.
pyridamole compared to placebo, with no significant The prostacyclin analogue, iloprost, was in-
difference between the two active treatment arms. The vestigated in a small study using a 3-day peri-pro-
high-dose arm showed a 24% absolute increase in cedural intravenous infusion regimen in conjunction
patency compared to placebo. Analysis of only those with long-term aspirin.10 This showed less platelet
patients who had angiographic evidence of patency accumulation at the dilatation site compared to
(83% of the patients enrolled) also showed a stat- patients not receiving antiplatelet treatment in the
istically significant benefit of the high-dose-aspirin/ peri-procedural period, but did not show a significant
difference in restenosis or occlusions.dipyridamole combination.
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as patency, occlusions and restenosis. Patency is some-
times defined on the basis of clinical signs and symp-
toms, sometimes determined by investigation,
sometimes confirmed by angiography or duplex ultra-
sound. Confusingly, patency is used to mean a non-
occluded vessel in some reports and a vessel without
occlusion or significant restenosis in others. The dif-
ficulty in measuring accurately the degree of restenosis
in a patent vessel should also be considered in the
interpretation of study results. In the absence of stand-
ardisation of usage, the definitions used should be
described very clearly in each study.
Another study design issue which complicates the
interpretation of results is the practice of entering moreFig. 1. Occlusion rates in studies comparing different doses of
aspirin. Groups compared in the same study are linked and occlusion than one PTA procedure in the same patient and
rates are shown with 95% confidence intervals.
counting the results separately. This invalidates one
of the assumptions of the statistical tests, namely that
the response to treatment in each subject is in-Discussion
dependent of the response in others.
Antithrombotic agents would be expected to reduceClinical trials in this indication regularly include
the incidence of thrombotic occlusions of the vessel andpatients with varying severity of lesions and clinical
platelet inhibitors might seem to be the logical choicesymptoms, but predominantly those with femoro-
given the evidence for platelet accumulation at the di-popliteal lesions and intermittent claudication. Assess-
latation site after peripheral angioplasties.14,15 Any in-ment of the results is hampered by the inconsistency
fluence of these agents on restenosis, however, remainsof definitions used in the past, for example in the
speculative, as the relation between early platelet ac-definitions of patency and recurrent stenosis. It is not
cumulation and thrombosis and late restenosis is notclear that this is better in the more recent trials than
clear at present. The majority of randomised trials inamongst those conducted and reported earlier. Al-
this indication have investigated the use of platelet in-though recommendations have been published,13 these
hibitors, but the evidence for their use is equivocal.have not been universally adopted.
Results of trials in this field are presented variously The two placebo-controlled trials of aspirin and
Table 2. Results of placebo-controlled studies of aspirin with dipyridamole. Results are expressed as the
percentage of patients without evidence of restenosis or occlusion at the end of the treatment period.
Study Treatment Patency Significance
Heiss 19908 Placebo 37% 0.04
Aspirin 300 mg/dipyridamole 49%
Aspirin 990 mg/dipyridamole 61%
PTA group 19946 Placebo 95% n.s.
Aspirin 50 mg/dipyridamole 90%
Table 3. Results of comparisons of platelet inhibitors and anticoagulants. Results are expressed as the percentage
of patients without restenosis or occlusion.
Study Treatment 12-month patency Significance
Pilger 19917* Aspirin/dipyridamole 83% n.s.
Anticoagulant 71%
Do 199411 Aspirin/dipyridamole 67% n.s.
Anticoagulant 52%
Schneider 198712* Ticlopidine 71% n.s.
Anticoagulant 69%
*Results derived from Kaplan–Meier plots.
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